Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years old.
• Both sexes.
• Patients with a history of prosthetic heart valves.
• Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.
Locations
Other Locations
Egypt
Kafrelsheikh University
RECRUITING
Kafr Ash Shaykh
Contact Information
Primary
Mohammed A Hammad, MD
drhammad879@gmail.com
00201015928694
Time Frame
Start Date: 2025-09-27
Estimated Completion Date: 2026-02-01
Participants
Target number of participants: 220
Treatments
Experimental: Group S
Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].
Active_comparator: Group C
Patients will be treated only with conventional anti-heart failure therapy as a control group.
Related Therapeutic Areas
Sponsors
Leads: Kafrelsheikh University